ALSO NOTED: Sepracor expands HQ; Sanofi profits jump 9.1 percent;

> Sepracor's layoffs weren't the only news to come out of its earnings announcement yesterday; the company also will expand its Boston-area offices with a 150,000-square-foot building next to HQ. Report

> Sanofi-Aventis reported a 9.1 percent spike in profits on strong sales of vaccines and its anti-clotting drug Plavix. Report

> Novo Nordisk reported a leap in third-quarter profits to $421 million, but lowered its full-year sales expectations because of currency exchange rates. Report

> Nycomed is buying Bradley Pharmaceuticals for $346 million cash, or $20 a share. Report

> India's Glenmark Pharmaceuticals posted profits of $18.4 million on revenues of $93.8 million for the quarter--growth of 50 percent and 88 percent respectively. Report

> Scientists at Brookhaven National Laboratory have added to the store of knowledge linking dopamine to obesity. Report

> Sangamo shares leap on stem cell tech advance. Report

> Researchers at the University of Cincinnati have identified a new target for drug developers out to control obesity and diabetes. Report

And Finally… Here's one reason to wear pajamas when you're on the road--or develop a new sleeping pill back home: an epidemic of sleepwalking through hotel lobbies. Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.